Tiziana (TLSA) Stock Up 21.26%; Submits Application for COVID-19 Treatment Antibody

Friday, July 31, 2020 9:41 AM | Neal Farmer

TIZIANA LF SCIE/S ADR (TLSA) is up 21.26% today after submitting an application for Nasal Administration of Foralumab to be used for treatment of COVID-19 patients. The fully human anti-CD3 monoclonal antibody (mAb) could potentially stimulate the immune system to reduce respiratory failures in COVID-19 patients. Recent clinical studies show that a combination of anti-inflammatory and anti-viral drugs may be more effective to treat patients and thus Tiziana believes that Foralumab can be used with other anti-viral drugs to improve efficiency. Tiziana stock has predictably surged upwards in price since the news as investors and traders process the news. TLSA stock had been trading under $4/share for most of late July but has seen a recent rise before and after this announcement and has now hit a new 52-week high with no current resistance.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Related Companies